Clinical trials: Advanced Gastric Cancer
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04535401
- Testing
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
This pilot clinical trial studies genetic analysis-guided irontecan hydrochloride dosing of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin (mFOLFIRINOX) in treating patients with gastroesophageal…
- Conditions
- Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Stage IIB Gastric Cancer, Stage IIIA Esophageal Adenocarcinoma
- Trial name
- NCT02366819
- Testing
- Oxaliplatin, Leucovorin Calcium, Irinotecan Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Gastric Cancer, RWS
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer…
- Conditions
- Gastric Cancer, RWS, PD-1 Immunotherapy
- Trial name
- NCT06485271
- Testing
- Camrelizumab, apatinib, chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Changzhi People's Hospital Affiliated to Changzhi Medical College
Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal squamous carcinoma, gastric…
- Conditions
- Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Colorectal Adenocarcinoma
- Trial name
- NCT03468244
- Testing
- Personalized mRNA Tumor Vaccine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Changhai Hospital
Neoplasms, Gastrointestinal Tract
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
This was an international multi-center trial that enrolled patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors had amplification of the ErbB2 (HER2)…
- Trial name
- NCT00680901
- Testing
- Lapatinib, Capecitabine, Oxaliplatin
- Where
- 183 sites in United States, Argentina and 21 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Gastric cancer is a highly heterogeneous tumor. The most commonly used clinical classifications of gastric cancer are Lauren classification (intestinal, diffuse, mixed) and World Health Organization(WHO) classification (papillary…
- Trial name
- NCT04863430
- Testing
- Apatinib, Oxaliplatin, S1
- Where
- China
- Sponsor
- Peking University
Chemotherapy, Gastric Cancer
FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis
In this study, patients with advanced gastric adenocarcinoma whose peritoneal metastasis and peritoneal nodule pathologically confirmed metastasis and/or exfoliative cytology were confirmed as the clinical stage of peritoneal…
- Trial name
- NCT04886193
- Testing
- FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Gastric Cancer Stage IV
Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death…
- Trial name
- NCT04592211
- Testing
- olaparib+pembrolizumab+paclitaxel
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Yonsei University
Gastric Cancer
Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy
This phase II trial aimed to assess the efficacy and safety of pemetrexed in patients with pretreated metastatic gastric cancer.
- Trial name
- NCT01953419
- Testing
- Pemetrexed disodium
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Gastric Cancer
Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
To evaluate the efficacy and safety of chemoradiotherapy combined with tirelizumab in the treatment of initial unresectable locally advanced gastric cancer or gastroesophageal junction cancer.
- Trial name
- NCT05528367
- Testing
- Nab-PTX,S-1,Tirelizumab, Chemoradiation
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Zhejiang Cancer Hospital
Gastroesophageal Cancer
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma.
- Trial name
- TroFuse-015 (NCT06356311)
- Testing
- Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan
- Where
- 168 sites in United States, Belgium and 22 more
- Volunteers
- 473 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Gastric Cancer
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of zanidatamab in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT04276493
- Testing
- Zanidatamab, Docetaxel, Tislelizumab
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 71 people
- Sponsor
- BeiGene
Breast Cancer, Gastric Cancer
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases. The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05678205
- Testing
- AB-201, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States, South Korea
- Sponsor
- Artiva Biotherapeutics, Inc.
Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
To evaluate the effectiveness and safety of SHR-A1811 combined with apatinib in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.
- Conditions
- Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Cancer
- Trial name
- NCT06666166
- Testing
- SHR-A1811 & Apartinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Yunpeng Liu
Carcinoma, Non-Small-Cell Lung, Gastric Cancer
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT04931654
- Testing
- AZD7789
- Where
- 21 sites in United States, Canada and 8 more
- Volunteers
- 136 people
- Sponsor
- AstraZeneca
Gastric Cancer, Chemotherapy Effect
Neo-adjuvant Chemotherapy Evluation in Gastric Cancer Patients Based on Circulating Exosomal LncRNA-GC1
The investigators hope that through the analysis and research to find determine whether lncRNA-GC1 could serve as a non-invasive biomarker for monitoring the neo-adjuvant chemotherapy response for personalized medicine for…
- Trial name
- NCT05647941
- Testing
- Detection of levels of circulating EV-derived lncRNA-GC1
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Chinese PLA General Hospital
Advanced Gastric Cancer, Locally Advanced Gastric Carcinoma
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to…
- Trial name
- NCT06727981
- Testing
- ICI plus Chemothearpy, Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Qilu Hospital of Shandong University
Gastric Cancer, Gastroesophageal Junction Cancer
IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
The overall efficacy of neoadjuvant treatment for advanced gastric cancer is limited due to significant heterogeneity in patient responses.
- Trial name
- IMPACT-GC (NCT06662110)
- Testing
- PSRscore
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with EGFR-positive, HER2-negative, inoperable locally advanced or metastatic gastric cancer.
- Trial name
- NCT05188209
- Testing
- MRG003
- Where
- 5 sites in China
- Volunteers
- 6 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Gastric Cancer, MSI-H
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a…
- Conditions
- Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
- Trial name
- CIME (NCT06346197)
- Testing
- Balstilimab, Botensilimab, Folfox Protocol
- Where
- 7 sites in France
- Volunteers
- 132 people
- Sponsor
- Centre Leon Berard